Tumor budding as an index to identify high-risk patients with stage II colon cancer

Diseases of the Colon and Rectum

Volumn 51, Issue 5, 2008, Pages 568-572

  Nakamura, Takatoshi ^a,d   Mitomi, Hiroyuki ^b   Kanazawa, Hideki ^b   Ohkura, Yasuo ^c   Watanabe, Masahiko ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KITASATO UNIVERSITY   (Japan)

Author keywords

Colon cancer; Prognosis; Stage II; Tumor budding

Indexed keywords

EOSIN; FLUOROURACIL; HEMATOXYLIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PROPORTIONAL HAZARDS MODEL; SEROSA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR BUDDING; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CHI-SQUARE DISTRIBUTION; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 43049097453     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/s10350-008-9192-9     Document Type: Article

References (22)

1. Sobin LH, Wittekind Ch. International Union Against Cancer (UICC). TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss, Inc., 2002.
2. Macdonald JS, Astrow AB. Adjuvant therapy of colon cancer. Semin Oncol 2001;28:30-40.
3. Merkel S, Wein A, Günther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with Stage II colon carcinoma. Cancer 2001;92:1435-43.
4. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001;44:1682-8.
5. Chapuis PH, Dent OF, Bokey EL, Newland RC, Sinclair G. Adverse histopathological findings as a guide to patient management after curative resection of node-positive colonic cancer. Br J Surg 2004;91:349-54.
6. Porschen R, Bermann A, Löffler T, Haack G, Rettig K, Anger Y, Strohmeyer G. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected Stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001;19:1787-94.
7. Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for Stage II, T3 colon cancer. Dis Colon Rectum 2003;46:1054-9.
8. Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in Stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum 2003;46:1400-6.
9. Okuyama T, Oya M, Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately differentiated rectal adenocarcinoma. J Surg Oncol 2003;83:42-7.
10. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40:127-32.
11. Okuyama T, Oya M, Yamaguchi M. Budding (sprouting) as a useful prognostic marker in colorectal mucinous carcinoma. Jpn J Clin Oncol 2002;32:412-6.
12. Park K-J, Choi H-J, Roh M-S, Kwon H-C, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum 2005;48:1597-602.
13. Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers: lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989;63:539-43.
14. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993;36:627-35.
15. WAF1/CIP1 are associated with metastasis in colorectal carcinomas. Hepato-Gastroenterology 2005;52:1421-6.
16. Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis Colon Rectum 2002;45:628-34.
17. Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepato-Gastroenterology 2005;52:1432-5.
18. Gabbert H, Wagner R, Moll R, Gerharz C-D. Tumor dedifferentiation: an important step in tumor invasion. Clin Expl Metastasis 1985;3:257-79.
19. Masaki T, Matsuoka H, Sugiyama M, et al. Laminin-5 γ 2 chain expression as a possible determinant of tumor aggressiveness in T1 colorectal carcinomas. Dig Dis Sci 2003;48:272-8.
20. Masaki T, Sugiyama M, Matsuoka H, et al. Coexpression of matrilysin and laminin-5 γ2 chain may contribute to tumor cell migration in colorectal carcinomas. Dig Dis Sci 2003;48:1262-7.
21. Guziñska-Ustymowicz K, Zalewski B, Kasacka I, Piotrowski Z, Skrzydlewska E. Activity of cathepsin B and D in colorectal cancer: relationships with tumour budding. Anticancer Res 2004;24:2847-52.
22. Jass JR, Baker M, Fraser L, et al. APC mutation and tumour budding in colorectal cancer. J Clin Pathol 2003;56:69-73.